Frontiers in Oncology | Cancer Molecular Targets and Therapeutics

Original Research

Published on 20 Jan 2023

14-3-3 and Smad2/3 are crucial mediators of atypical-PKCs: Implications for neuroblastoma progression

in Cancer Molecular Targets and Therapeutics

S. Breedy
W.S. Ratnayake
L. Lajmi
R. Hill
M. Acevedo-Duncan

Frontiers in Oncology

doi 10.3389/fonc.2023.1051516

2,669 views
2 citations

Review

Published on 19 Jan 2023

The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy

in Cancer Molecular Targets and Therapeutics

Hendrik Setia Budi
Laith A. Younus
Methaq Hadi Lafta
Sameena Parveen
Hawraa Jabbar Mohammad
Zahraa Haleem Al-qaim
Mohammed Abed Jawad
Rosario Mireya Romero Parra
Yasser Fakri Mustafa
Firas Rahi Alhachami

Frontiers in Oncology

doi 10.3389/fonc.2022.1067974

4,921 views
32 citations

Mini Review

Published on 19 Jan 2023

Patient-derived models: Advanced tools for precision medicine in neuroblastoma

in Cancer Molecular Targets and Therapeutics

Kristina Aaltonen
Katarzyna Radke
Aleksandra Adamska
Alexandra Seger
Adriana Mañas
Daniel Bexell

Frontiers in Oncology

doi 10.3389/fonc.2022.1085270

5,181 views
11 citations

Original Research

Published on 18 Jan 2023

The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer

in Cancer Molecular Targets and Therapeutics

Ryan M. Finnegan
Ahmed M. Elshazly
Nipa H. Patel
Liliya Tyutyunyk-Massey
Tammy H. Tran
Vishnu Kumarasamy
Erik S. Knudsen
David A. Gewirtz

Frontiers in Oncology

doi 10.3389/fonc.2022.966441

4,488 views
18 citations

Original Research

Published on 16 Jan 2023

FOXO3 gene hypermethylation and its marked downregulation in breast cancer cases: A study on female patients

in Cancer Molecular Targets and Therapeutics

Mohammad Aasif Khan
Sadaf
Irfan Ahmad
Abdulaziz A. Aloliqi
Alaa Abdulaziz Eisa
Mohammad Zeeshan Najm
Maria Habib
Saad Mustafa
Sheersh Massey
Zoya Malik

Frontiers in Oncology

doi 10.3389/fonc.2022.1078051

3,202 views
5 citations

Review

Published on 13 Jan 2023

Crosstalk between microwave ablation and ferroptosis: The next hot topic?

in Cancer Molecular Targets and Therapeutics

Lu Yu
Min Cheng
Jie Liu
Xin Ye
Zhigang Wei
Jiamei Xu
Qi Xie
Jing Liang

Frontiers in Oncology

doi 10.3389/fonc.2023.1099731

3,708 views
7 citations

Original Research

Published on 13 Jan 2023

Evaluating the local expression pattern of IGF-1R in tumor tissues and the circulating levels of IGF-1, IGFBP-1, and IGFBP-3 in the blood of patients with different primary bone tumors

in Cancer Molecular Targets and Therapeutics

Mohammad Amin Vaezi
Amir Reza Eghtedari
Banafsheh Safizadeh
Pegah Babaheidarian
Vahid Salimi
Fatemeh Adjaminezhad-Fard
Sahar Yarahmadi
Alireza Mirzaei
Mahtab Rahbar
Masoumeh Tavakoli-Yaraki

Frontiers in Oncology

doi 10.3389/fonc.2022.1096438

2,655 views
5 citations

Case Report

Published on 12 Jan 2023

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review

in Cancer Molecular Targets and Therapeutics

Yuri Isaka
Akinori Sasaki
Akira Saito
Yasuaki Motomura
Yayoi Ando
Yoshiaki Nakamura

Frontiers in Oncology

doi 10.3389/fonc.2022.1064944

1,660 views
1 citation

Original Research

Published on 12 Jan 2023

Development of anoikis-related genes signature to predict the prognosis in gastric cancer patients

in Cancer Molecular Targets and Therapeutics

Jie Cao
Kai Hong
Yuepeng Cao
Kenan Cen
Yifeng Mai
Ying Dai
Guifang Ouyang
Qitian Mu
Yangyang Guo

Frontiers in Oncology

doi 10.3389/fonc.2022.1096608

4,184 views
14 citations

Case Report

Published on 10 Jan 2023

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib

in Cancer Molecular Targets and Therapeutics

Wen-Chi Wu
Ming-Huang Chen

Frontiers in Oncology

doi 10.3389/fonc.2022.1031396

1,961 views
1 citation

Review

Published on 10 Jan 2023

Potassium channels: Novel targets for tumor diagnosis and chemoresistance

in Cancer Molecular Targets and Therapeutics

Meizeng Li
Peijie Tian
Qing Zhao
Xialin Ma
Yunxiang Zhang

Frontiers in Oncology

doi 10.3389/fonc.2022.1074469

5,928 views
23 citations

Brief Research Report

Published on 10 Jan 2023

Mild oxidative stress protects against chemotherapy-induced hair loss

in Cancer Molecular Targets and Therapeutics

Yusheng Zhang
Joaquin J. Jimenez

Frontiers in Oncology

doi 10.3389/fonc.2022.1078916

3,099 views
2 citations

Review

Published on 09 Jan 2023

CircCCDC66: Emerging roles and potential clinical values in malignant tumors

in Cancer Molecular Targets and Therapeutics

Xiaoxiao Wang
Chao Zhang
Huangqin Song
Junlong Yuan
Lei Zhang
Jiefeng He

Frontiers in Oncology

doi 10.3389/fonc.2022.1061007

3,534 views
7 citations

Correction

Published on 06 Jan 2023

Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

in Cancer Molecular Targets and Therapeutics

Sunisa Prasopporn
Orawan Suppramote
Ben Ponvilawan
Chanette Jamyuang
Jantappapa Chanthercrob
Amphun Chaiboonchoe
Pimkanya More-Krong
Kamonchanok Kongsri
Monthira Suntiparpluacha
Rawisak Chanwat

Frontiers in Oncology

doi 10.3389/fonc.2022.1124912

1,364 views
1 citation

Review

Published on 06 Jan 2023

Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening

in Cancer Molecular Targets and Therapeutics

Cuiying Xie
Ancheng Gu
Muhammad Khan
Xiangcao Yao
Leping Chen
Jiali He
Fumiao Yuan
Ping Wang
Yufan Yang
Yerong Wei

Frontiers in Oncology

doi 10.3389/fonc.2022.1105454

4,295 views
10 citations

Systematic Review

Published on 05 Jan 2023

Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis

in Cancer Molecular Targets and Therapeutics

Peizhuo Yao
Yinbin Zhang
Shuqun Zhang
Xinyu Wei
Yanbin Liu
Chong Du
Mingyou Hu
Cong Feng
Jia Li
Fang Zhao

Frontiers in Oncology

doi 10.3389/fonc.2022.1039882

6,587 views
12 citations